In our twice-weekly chats, I often suggest investments that are part of large tech sectors.
For instance, the life sciences field defines huge. Just the prescription drug segment alone will be worth $1.2 trillion by 2024, according to data from Statista.
So, you might be wondering why I am focused on a medical area that will be worth just 0.1% of that figure over roughly the same time frame.
It’s a fair question. The answer is pretty basic. A high-octane leader
focused on specialty drugs can make a killing.
And the one I’m going to reveal to you today defines profit machine. It’s on pace to double per-share earnings in as little as a year.
With that in mind, let me show you five reasons why this wealth-building biotech firm should at the very least be on your radar screen….
I want to start today’s chat with a tech-investing challenge.
How many of you can claim you have a stock in your portfolio that is up nearly 230% in just 16 months?
As impressive as that return sounds, it actually understates the strength of the stock I have in mind. It’s a medical device leader that recently received approval for a Covid-19 test.
It’s up 120 in the past two months alone…
But this is no flash in the pan. Even before that breakthrough occurred, the stock was a bona fide market crusher
From roughly the beginning of 2019 through the correction that began on February 19, the stock was ahead of the S&P 500 by an amazing 278.5%.
The firm I have in mind is leading the medical device market as part of a trend toward remote patient monitory.
With the coronavirus still fresh on everyone’s minds, the investment thesis is only getting better.
So, today I’m going to reveal why the stock could double in as little as three years and show you how to get in on the action…
